Journal of Gastroenterology

, Volume 43, Issue 11, pp 875–880

Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer

  • Koichi Taira
  • Narikazu Boku
  • Akira Fukutomi
  • Yusuke Onozawa
  • Shuichi Hironaka
  • Takayuki Yoshino
  • Hirofumi Yasui
  • Kentaro Yamazaki
  • Keisei Taku
  • Takayuki Hashimoto
  • Tetsuo Nishimura
Liver, Pancreas, and Biliary Tract
  • 58 Downloads

Abstract

Background

Many studies of concurrent chemoradiation therapy with 5-fluorouracil (5-FU) for locally advanced pancreatic cancer have been reported with a median survival time of approximately 10 months. Recently, gemcitabine (GEM) has been administered immediately after chemoradiation. The clinical outcome of chemoradiation therapy in conjunction with 5-FU and second-line chemotherapy with GEM after disease progression has not been clarified.

Methods

Patients with locally advanced pancreatic cancer were treated with concurrent radiation therapy (1.8 Gy/fraction; total dose, 50.4 Gy) with 5-FU (200 mg/m2 every day) until disease progression, followed by GEM (1000 mg/m2, days 1, 8, 15, and every 4 weeks) as second-line therapy.

Results

Of the 18 patients with locally advanced pancreatic cancer who received chemoradiation therapy with 5-FU, there were three partial responses, giving a response rate of 17%. The median time to progression was 170 days. The median survival time was 443 days. During chemoradiation therapy, the incidences of grade 3 or 4 anorexia, nausea, mucositis, and gastric ulcer were 33%, 22%, 17%, and 17%, respectively. Sixteen patients received second-line chemotherapy with GEM, of whom one patient had a partial response. The median time to progression from the initiation of GEM was 113 days, and median overall survival time was 231 days. Major toxicities were hematological toxicities: grade 3 or 4 leukopenia in 75% and anemia in 31%.

Conclusions

The treatment strategy with concurrent chemoradiation and maintenance chemotherapy with 5-FU followed by second-line chemotherapy with GEM may be an option for locally advanced pancreatic cancer.

Key words

locally advanced pancreatic cancer chemoradiation 5-fluorouracil gemcitabine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995;221:721–731.PubMedCrossRefGoogle Scholar
  2. 2.
    Sohn T, Yeo C, Cameron J, Koniaris L, Kaushal S, Abrams R, et al. Resected adenocarcinoma of the pancreas-616 patients; results, outcomes, and prognostic indicators. J Gastrointest Surg 2004;4:567–579.CrossRefGoogle Scholar
  3. 3.
    Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969;2:865–867.PubMedCrossRefGoogle Scholar
  4. 4.
    Moertel CG, Frytak S, Hahn RG, O’Connell MJ, Reitemeier RJ, Rubin J, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981;48:1705–1710.PubMedCrossRefGoogle Scholar
  5. 5.
    Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combinedmodality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988;80:751–755.CrossRefGoogle Scholar
  6. 6.
    Klaassen DJ, MacIntyre JM, Catton GE, Enqstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-an Eastern Cooperative Oncology Group study. J Clin Oncol 1985;3:373–378.PubMedGoogle Scholar
  7. 7.
    Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403–2413.PubMedGoogle Scholar
  8. 8.
    Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M, et al. Is the therapeutic index better with gemcitabinebased chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 2002;52:1293–1302.PubMedCrossRefGoogle Scholar
  9. 9.
    Regine WF, Winter KW, Abrams R, Safran H, Hoffman JP, Konski A, et al. RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. 2006 American Society of Clinical Oncology annual meeting;2006 June 2–6, Atlanta, USA.Google Scholar
  10. 10.
    Chauffert B, Mornex F, Bonnetain F, Triboulet JP, Bouche O, Rougier P, et al. Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study. 2006 American Society of Clinical Oncology annual meeting;2006 June 2–6, Atlanta, USA.Google Scholar
  11. 11.
    Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946–3952.PubMedCrossRefGoogle Scholar
  12. 12.
    World Health Organization. WHO handbook for reporting results of cancer treatment. WHO Offset Publication No. 48. Geneva: World Health Organization; 1979.Google Scholar
  13. 13.
    Ishii H, Okada S, Tokuuye K, Nose H, Okusaka T, Yoshimori M, et al. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 1997;79:1516–1520.PubMedCrossRefGoogle Scholar
  14. 14.
    Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma. Cancer 2002;94:902–910.PubMedCrossRefGoogle Scholar
  15. 15.
    Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776–3783.PubMedCrossRefGoogle Scholar
  16. 16.
    Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509–3516.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2008

Authors and Affiliations

  • Koichi Taira
    • 1
  • Narikazu Boku
    • 1
  • Akira Fukutomi
    • 1
  • Yusuke Onozawa
    • 1
  • Shuichi Hironaka
    • 1
  • Takayuki Yoshino
    • 1
  • Hirofumi Yasui
    • 1
  • Kentaro Yamazaki
    • 1
  • Keisei Taku
    • 1
  • Takayuki Hashimoto
    • 2
  • Tetsuo Nishimura
    • 2
  1. 1.Divison of Gastrointestinal OncologyShizuoka Cancer CenterShizuokaJapan
  2. 2.Division of Radiation OncologyShizuoka Cancer CenterShizuokaJapan
  3. 3.Department of GastroenterologyOsaka City University Graduate School of MedicineOsakaJapan

Personalised recommendations